A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Study sponsor: Alector Inc. · ALEC
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-06-05Actual
Enrollment · participants33Actual
Source updated2025-12-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.